Author(s):
Kajal Pansare, Yogesh Ahire, Vinod Bairagi, Ganesh Sonawane, Chandrashekhar Patil, Sunil Mahajan, Deepak Sonawane
Email(s):
kajalgsonawane@gmail.com
DOI:
10.52711/2321-5836.2026.00021 
Address:
Kajal Pansare1*, Yogesh Ahire2, Vinod Bairagi3, Ganesh Sonawane4, Chandrashekhar Patil5, Sunil Mahajan6, Deepak Sonawane6
1Research Scholar, Savitribai Phule Pune University Affiliated, KBHSS Trusts Institute of Pharmacy, Malegaon, Dist – Nashik - 423203 (India)
2Associate Professor, Savitribai Phule Pune University Affiliated, KBHSS Trusts Institute of Pharmacy, Malegaon, Dist – Nashik - 423203 (India)
3Professor, Savitribai Phule Pune University Affiliated, KBHSS Trusts Institute of Pharmacy, Malegaon, Dist – Nashik - 423203 (India)
4Assistant Professor, Savitribai Phule Pune University Affiliated, Divine College of Pharmacy, Satana, Dist - Nashik - 423301 (India)
5Associate Professor, Savitribai Phule Pune University Affiliated, Divine College of Pharmacy, Satana, Dist – Nashik - 423301 (India)
6Professor, Savitribai Phule Pune University Affiliated, Divine College of Pharmacy, Satana, Dist – Nashik - 423301 (India)
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2026
ABSTRACT:
Nephropathy, resulting from diabetes, drug toxicity, or oxidative stress, is a major contributor to chronic kidney disease worldwide. Natural products with antioxidant, anti-inflammatory, and immunomodulatory properties are gaining attention as potential nephroprotective agents. Bromelain, a cysteine protease derived from pineapple (Ananas comosus), has demonstrated significant renoprotective effects in preclinical models of diabetic, drug-induced, and oxidative stress–related nephropathy. Mechanistically, bromelain attenuates oxidative stress, inflammation, apoptosis, and fibrosis while enhancing antioxidant defense and modulating immune responses. Its favorable safety profile, oral bioavailability, and nutraceutical potential make it a promising adjunct or alternative therapy. However, clinical evidence in human nephropathy remains limited, and challenges such as enzyme stability, standardization, and bioavailability need to be addressed. Future strategies involving nanotechnology-based delivery, combination therapy with other natural products, and precision medicine approaches may enhance its therapeutic potential. This review summarizes the mechanisms, experimental evidence, clinical relevance, and future perspectives of bromelain as a renoprotective agent, highlighting its promise in kidney disease management and the need for further clinical validation.
Cite this article:
Kajal Pansare, Yogesh Ahire, Vinod Bairagi, Ganesh Sonawane, Chandrashekhar Patil, Sunil Mahajan, Deepak Sonawane. Renoprotective Potential of Bromelain: Mechanisms and Therapeutic Applications in Nephropathy. Research Journal of Pharmacology and Pharmacodynamics.2026;18(2):152-8. doi: 10.52711/2321-5836.2026.00021
Cite(Electronic):
Kajal Pansare, Yogesh Ahire, Vinod Bairagi, Ganesh Sonawane, Chandrashekhar Patil, Sunil Mahajan, Deepak Sonawane. Renoprotective Potential of Bromelain: Mechanisms and Therapeutic Applications in Nephropathy. Research Journal of Pharmacology and Pharmacodynamics.2026;18(2):152-8. doi: 10.52711/2321-5836.2026.00021 Available on: https://rjppd.org/AbstractView.aspx?PID=2026-18-2-6
11. REFERENCES:
1. Jin Q, Zhang L, Zhang Y, et al. Oxidative stress and inflammation in diabetic nephropathy. Front Immunol. 2023; 14:1185317. doi:10.3389/fimmu.2023.1185317.
2. Xie Y, Bowe B, Mokdad AH, et al. Global, regional, and national burden of chronic kidney disease, 1990–2021: systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health. 2025; 25:1–13. doi:10.1186/s12889-025-21851-z.
3. El-Demerdash FM, Baghdadi HH, Ghanem NF, Mhanna ABA. Nephroprotective role of bromelain against oxidative injury induced by aluminum chloride in rats. Food Chem Toxicol. 2020; 145:111710. doi: 10.1016/j.fct.2020.111710.
4. Guo J, Zhang L, Han C, et al. Global burden inequality of chronic kidney disease, 1990–2021: analysis of GBD 2021. Front Med. 2025; 12:1501175. doi:10.3389/fmed.2024.1501175.
5. Wang L, He Y, Han C, et al. Global burden of chronic kidney disease and risk factors, 1990–2021: an analysis of the GBD Study 2021. Front Public Health. 2025; 13: 1542329. doi:10.3389/fpubh.2025.1542329.
6. Kumar V, Mangla B, Javed S, Ahsan W, Kumar P, Garg V, Dureja H. Bromelain: a review of its mechanisms, pharmacological effects and potential applications. Food Funct. 2023; 14(18): 8101–8128. doi:10.1039/D3FO01060K.
7. Chakraborty AJ, Banerjee A, Das S. Bromelain: a potential bioactive compound in the management of various diseases. Foods. 2021; 11(4): 317. doi:10.3390/foods11040317.
8. Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012; 2012: 976203. doi:10.1155/2012/976203.
9. Kumar V, Mangla B, Javed S, Ahsan W, Kumar P, Garg V, Dureja H. Bromelain: a review of its mechanisms, pharmacological effects and potential applications. Food Funct. 2023; 14(18): 8101–8128. doi:10.1039/D3FO01060K.
10. Agrawal N, Rajput S, Singh P. Bromelain: a potent phytomedicine. Nutrients. 2022; 14(8): 1623. doi:10.3390/nu14081623.
11. Pavan R, Jain S, Kumar A. Stability and enzymatic activity of bromelain: pharmacological considerations. Int J Biol Macromol. 2012; 50(3): 808–818. doi:10.1016/j.ijbiomac.2011.12.012.
12. Hale LP, Greer PK, Trinh CT, Gottfried MR. Absorption of orally administered bromelain in healthy volunteers. Clin Pharmacol Ther. 2005; 78(3): 306–314. doi:10.1016/j.clpt.2005.05.010.
13. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol. 2008; 128(1): 66–74. doi:10.1016/j.clim.2008.04.002.
14. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93(1): 137–188. doi:10.1152/physrev.00045.2011.
15. Kim J, Kim S, Choi HS. Mitochondrial dysfunction and apoptosis in kidney diseases. Kidney Res Clin Pract. 2018; 37(2): 111–119. doi: 10.23876/j.krcp.2018.37.2.111.
16. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006; 55(1): 225–233. doi:10.2337/diabetes.55.01.06.db05-0774.
17. Szkudelski T. The mechanism of alloxan and streptozotocin action in β-cells of the rat pancreas. Physiol Res. 2001; 50(6): 537–546.
18. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008; 51(2): 216–226. doi:10.1007/s00125-007-0886-7.
19. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73(9): 994–1007. doi:10.1038/sj.ki.5002787.
20. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol. 2006; 44(8): 1173–1183. doi: 10.1016/j.fct.2006.03.002.
21. Pansare, K., Ahire, Y., & Bairagi, V. Nephroprotective Effect of Naringenin and Bromelain Against Cisplatin-Induced Renal Toxicity in Rats. Trends in Sciences. 2024; 22(11): 10681. doi:10.48048/tis.2025.10681
22. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol. 2008; 128(1): 66–74. doi: 10.1016/j.clim.2008.04.002.
23. Chobotova K, Vernallis AB, Majid FA. Bromelain’s activity and potential as an anti-inflammatory agent. Inflamm Res. 2010; 59(12): 115–123. doi:10.1007/s00011-010-0228-7.
24. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001; 58(9): 1234–1245. doi:10.1007/PL00000936.
25. Pavan R, Shraddha, Jain S, Kumar A. Mechanisms of bromelain-induced cytoprotection. Biotechnol Res Int. 2012; 2012: 976203. doi:10.1155/2012/976203.
26. Majid FA, Chobotova K. Cytoprotective effects of bromelain in oxidative stress models. Mol Cell Biochem. 2008; 308(1–2): 131–137. doi:10.1007/s11010-007-9646-4.
27. Agrawal N, Rajput S, Singh P. Anti-fibrotic and anti-inflammatory effects of bromelain. Nutrients. 2022; 14(8): 1623. doi:10.3390/nu14081623.
28. Hale LP, Greer PK. Immunomodulatory effects of bromelain. Clin Immunol. 2004; 112(2): 149–156. doi: 10.1016/j.clim.2004.04.001.
29. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. J Ethnopharmacol. 1988; 22(2): 191–203. doi:10.1016/0378-8741(88)90009-4.
30. El-Demerdash FM, Baghdadi HH, Ghanem NF, Mhanna ABA. Nephroprotective role of bromelain against oxidative injury induced by aluminum chloride in rats. Food Chem Toxicol. 2020; 145: 111710. doi: 10.1016/j.fct.2020.111710.
31. Sharma S, Singh G, Kumar A. Protective effect of bromelain in streptozotocin-induced diabetic nephropathy in rats. Biomed Pharmacother. 2021; 138: 111453. doi: 10.1016/j.biopha.2021.111453.
32. Rajeshkumar S, Karthikeyan S. Effect of bromelain on renal histopathology in alloxan-induced diabetic nephropathy. J Pharm Pharmacol. 2022; 74(5): 709–718. doi:10.1093/jpp/rgac022.
33. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and protective strategies. Kidney Int. 2008; 73(9): 994–1007. doi:10.1038/sj.ki.5002787.
34. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: recent research. Food Chem Toxicol. 2006; 44(8): 1173–1183. doi: 10.1016/j.fct.2006.03.002.
35. Shukla S, Kumar P. Protective effects of bromelain against heavy metal–induced nephrotoxicity. Toxicol Rep. 2020; 7: 688–697. doi: 10.1016/j.toxrep.2020.05.008.
36. Tanaka M, Kubo M, Ohtani K. Bromelain reduces ischemia-reperfusion-induced renal injury in rat model. Nephrology (Carlton). 2018; 23(6): 543–551. doi:10.1111/nep.13233.
37. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain reduces hydrogen peroxide–induced apoptosis in renal tubular cells. Clin Immunol. 2008; 128(1): 66–74. doi: 10.1016/j.clim.2008.04.002.
38. Majid FA, Chobotova K. Cytoprotective effects of bromelain in renal epithelial cells under oxidative stress. Mol Cell Biochem. 2008; 308(1–2): 131–137. doi:10.1007/s11010-007-9646-4.
39. Agrawal N, Rajput S, Singh P. Comparative nephroprotective effects of bromelain and N-acetylcysteine in experimental nephropathy. Nutrients. 2022; 14(8): 1623. doi:10.3390/nu14081623.
40. Sharma S, Kumar G. Bromelain versus ACE inhibitors in streptozotocin-induced nephropathy: a comparative study. Biomed Pharmacother. 2021; 143:112200. doi: 10.1016/j.biopha.2021.112200.
41. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. J Ethnopharmacol. 1988; 22(2): 191–203. doi:10.1016/0378-8741(88)90009-4.
42. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment modulates inflammatory responses in humans. Clin Immunol. 2008;128(1):66–74. doi: 10.1016/j.clim.2008.04.002.
43. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001; 58(9): 1234–1245. doi:10.1007/PL00000936.
44. Hale LP, Greer PK. Immunomodulatory effects of bromelain. Clin Immunol. 2004; 112(2): 149–156. doi: 10.1016/j.clim.2004.04.001.
45. Agrawal N, Rajput S, Singh P. Comparative nephroprotective effects of bromelain and conventional antioxidants. Nutrients. 2022; 14(8):1623. doi:10.3390/nu14081623.
46. Kumar V, Mangla B, Javed S, Ahsan W, Kumar P, Garg V, Dureja H. Bromelain: a review of its mechanisms, pharmacological effects and potential applications. Food Funct. 2023; 14(18): 8101–8128. doi:10.1039/D3FO01060K.
47. Chobotova K, Vernallis AB, Majid FA. Bromelain’s activity and clinical applications as a nutraceutical. Inflamm Res. 2010; 59(12): 115–123. doi:10.1007/s00011-010-0228-7.
48. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. J Ethnopharmacol. 1988; 22(2): 191–203. doi:10.1016/0378-8741(88)90009-4.
49. Hale LP, Greer PK, Trinh CT, Gottfried MR. Absorption and systemic effects of orally administered bromelain in healthy volunteers. Clin Pharmacol Ther. 2005; 78(3): 306–314. doi: 10.1016/j.clpt.2005.05.010.
50. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001; 58(9): 1234–1245. doi:10.1007/PL00000936.
51. Chobotova K, Vernallis AB, Majid FA. Bromelain’s activity and clinical applications as a nutraceutical. Inflamm Res. 2010; 59(12): 115–123. doi:10.1007/s00011-010-0228-7.
52. Klein G, Kullich W, Schatz H. Effects of bromelain on coagulation and fibrinolysis in humans. Thromb Res. 2000; 97(6): 395–402. doi:10.1016/s0049-3848(99)00223-5.
53. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain improves absorption of certain antibiotics in humans. Clin Immunol. 2008; 128(1): 66–74. doi: 10.1016/j.clim.2008.04.002.
54. Hale LP, Greer PK. Bromelain as an adjunct in chemotherapy: pharmacokinetic considerations. Clin Immunol. 2004; 112(2): 149–156. doi: 10.1016/j.clim.2004.04.001.
55. Agrawal N, Rajput S, Singh P. Bromelain: dosing, safety, and therapeutic applications. Nutrients. 2022; 14(8): 1623. doi:10.3390/nu14081623.
56. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. J Ethnopharmacol. 1988; 22(2): 191–203. doi:10.1016/0378-8741(88)90009-4.
57. Hale LP, Greer PK. Bromelain in precision medicine and drug repurposing. Clin Immunol. 2004; 112(2): 149–156. doi: 10.1016/j.clim.2004.04.001.